

31 October 2025

Solvonis Therapeutics plc
("Solvonis" or the "Company")

Total Voting Rights

Solvonis Therapeutics plc (LSE: SVNS), an emerging biopharmaceutical company developing novel medicines for high-burden central nervous system ("CNS") disorders, confirms that the Company's issued share capital as at the date of this announcement comprises 6,806,403,493 Ordinary Shares with one voting right each. The Company does not hold any Ordinary Shares in treasury. Therefore, the total number of Ordinary Shares and voting rights in the Company is 6,806,403,493.

This includes an amendment to the issue of shares announced on 31 October 2025 where the correct figure to be issued and admitted is 23,636,362. The original figure announced was 26,636,362.

The above figure may be used by shareholders in the Company as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the share capital of the Company.

Enquiries:

Solvonis Therapeutics plc

anthony@solvonis.com

Anthony Tennyson, CEO & Executive Director

Singer Capital Markets (Corporate Broker)

Phil Davies +44 (0) 20 7496 3000

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact ms@seg.com or visit www.ms.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

TVREASEFDSPSFFA